Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T50918 | ||||
Target Name | Muscarinic acetylcholine receptor M5 | ||||
Target Type | Successful |
||||
Drug Potency against Target | N-methoxyquinuclidine-3-carboximidoyl chloride | Drug Info | IC50 = 1100 nM | ||
7-Pyrrolidin-1-yl-hept-5-yn-2-one | Drug Info | IC50 = 7280 nM | |||
BRL-55473 | Drug Info | IC50 = 470 nM | |||
Darifenacin | Drug Info | Ki = 10 nM | [552263] | ||
3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one | Drug Info | IC50 = 5696 nM | |||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | Ki < 1000 nM | [531079] | ||
N-DESMETHYLCLOZAPINE | Drug Info | Ki = 51 nM | [531079] | ||
Pilocarpine | Drug Info | EC50 = 845 nM | |||
N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide | Drug Info | IC50 = 21.6 nM | |||
FM1-10 | Drug Info | Ki = 228 nM | [529178] | ||
Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester | Drug Info | Ki = 0.95 nM | [525826] | ||
Mepenzolate | Drug Info | IC50 = 1000 nM | [553125] | ||
Pirenzepine | Drug Info | Ki = 63 nM | [552263] | ||
ISOLOXAPINE | Drug Info | IC50 = 49 nM | [533577] | ||
1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione | Drug Info | IC50 = 15 nM | [533345] | ||
Atropine | Drug Info | Ki = 0.63 nM | [552263] | ||
3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane | Drug Info | IC50 = 16000 nM | [527344] | ||
SULFOARECOLINE | Drug Info | IC50 = 1.4 nM | [533450] | ||
7-Dimethylamino-hept-5-yn-2-one | Drug Info | IC50 = 68 nM | |||
VU0238429 | Drug Info | Ki = 159 nM | [530133] | ||
Tolterodine | Drug Info | Ki = 3.98 nM | [552263] | ||
CREMASTRINE | Drug Info | IC50 = 1220 nM | [527523] | ||
GNF-PF-5618 | Drug Info | Ki = 1180 nM | [527653] | ||
1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea | Drug Info | Ki = 10700 nM | [527029] | ||
2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one | Drug Info | Ki = 6.7 nM | [534723] | ||
Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester | Drug Info | Ki = 440 nM | [525826] | ||
Homatropine Methylbromide | Drug Info | IC50 = 9000000 nM | |||
PF-3409409 | Drug Info | Ki = 1800 nM | [530265] | ||
6-Dimethylamino-2-methyl-hex-4-ynal oxime | Drug Info | IC50 = 13230 nM | |||
ISOCLOZAPINE | Drug Info | IC50 = 55 nM | [530313] | ||
N-methoxyquinuclidine-3-carboximidoyl fluoride | Drug Info | IC50 = 2000 nM | |||
FLUMEZAPINE | Drug Info | IC50 = 80 nM | [533165] | ||
ACECLIDINE | Drug Info | IC50 = 510 nM | [534044] | ||
FM1-43 | Drug Info | Ki = 83 nM | [529178] | ||
7-Dimethylamino-3-methyl-hept-5-yn-2-one | Drug Info | IC50 = 101 nM | |||
GSK961081 | Drug Info | Ki < 10 nM | [552942] | ||
Procyclidine | Drug Info | IC50 =70 nM | [553144] | ||
2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime | Drug Info | IC50 = 1928 nM | |||
Action against Disease Model | Trospium | Trospi uM chloride is a quaternary ammoni uM compound, which is a competitive antagonist at muscarinic cholinergic receptors. Preclinical studies using porcine and h uMan detrusor muscle strips demonstrated that trospi uM chloride was many-fold more potent than oxybutynin and tolterodine in inhibiting contractile responses to carbachol and electrical stimulation. The drug ispoorly bioavailable orally (< 10%) and food reduces absorption by 70%- 80%. It is predominantly eliminated renally as unchanged compound. Trospi uM chloride, dosed 20 mg twice daily, is significantlysuperior to placebo in improving cystometric parameters, reducing urinary frequency, reducing incontinence episodes, and increasing urine vol uMe per micturition. In active-controlled trials, trospi uM chloride was at least equivalent to immediate-release formulations of oxybutynin and tolterodine in efficacy and tolerability. The most problematic adverse effects of trospi uM chloride are the anticholinergic effects of dry mouth and constipation. Comparative efficacy/tolerability data with long-acting formulations of oxybutynin and tolterodine as well as other anticholinergics such as solifenacin and darifenacin are not available. On the basis of available data, trospi uM chloride does not appear to be a substantial advance upon existing anticholinergics in the management of urge urinary incontinence. | [552802] | Drug Info | |
Flavoxate | flavoxate caused a concentration-dependent relaxation of h uMan urinary bladder precontracted by K+ with much higher potency (IC50: 2000 nM) | Drug Info | |||
Oxyphencyclimine | Inhibition of H-Quinuclidinyl Benzilate (H-QNB) binding to Bovine Cortex. IC50 for (R)-(+)-Oxyphencyclimine HCL: 25.8 nM | Drug Info | |||
Promazine | IC50 on SARS virus (Urbani strain) in African green monkey kidney cells: 11200nM | [552810] | Drug Info | ||
Ipratropium | IC50 of EFS-induced contraction in Guinea pig/h uMan trachea: 0.58 nM/1.36 nM | [552190] | Drug Info | ||
Bethanechol | IC50 for porcine and h uMan detrusor muscle: 80000 nM | [553131] | Drug Info | ||
References | |||||
Ref 552263 | Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001 Aug;22(8):409-14. | ||||
Ref 531079 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. | ||||
Ref 552802 | Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag. 2005 Jun;1(2):157-67. | ||||
Ref 531079 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. | ||||
Ref 529178 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. Epub 2007 Nov 17.Design and synthesis of a fluorescent muscarinic antagonist. | ||||
Ref 525826 | J Med Chem. 2000 Jun 29;43(13):2514-22.6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. | ||||
Ref 553125 | Low temperature and muscarinic receptor activities. Cryobiology. 1989 Oct;26(5):485-95. | ||||
Ref 552263 | Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001 Aug;22(8):409-14. | ||||
Ref 533577 | J Med Chem. 1981 Sep;24(9):1021-6.Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. | ||||
Ref 533345 | J Med Chem. 1989 May;32(5):1057-62.Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. | ||||
Ref 552263 | Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001 Aug;22(8):409-14. | ||||
Ref 527344 | J Med Chem. 1992 Apr 3;35(7):1280-90.Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. | ||||
Ref 533450 | J Med Chem. 1988 Jul;31(7):1312-6.Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. | ||||
Ref 530133 | J Med Chem. 2009 Jun 11;52(11):3445-8.Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins. | ||||
Ref 552263 | Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001 Aug;22(8):409-14. | ||||
Ref 527523 | J Nat Prod. 2005 Apr;68(4):572-3.Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. | ||||
Ref 527653 | J Nat Prod. 2005 Jul;68(7):1061-5.Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. | ||||
Ref 527029 | J Med Chem. 1992 Aug 21;35(17):3270-9.Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. | ||||
Ref 534723 | J Med Chem. 1998 Oct 22;41(22):4181-5.Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. | ||||
Ref 525826 | J Med Chem. 2000 Jun 29;43(13):2514-22.6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. | ||||
Ref 552810 | Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model. Antiviral Res. 2008 Aug;79(2):105-13. doi: 10.1016/j.antiviral.2007.12.005. Epub 2008 Jan 11. | ||||
Ref 530265 | Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. Epub 2009 Jul 2.Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. | ||||
Ref 530313 | J Med Chem. 1990 Feb;33(2):809-14.Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. | ||||
Ref 533165 | J Med Chem. 1989 Dec;32(12):2573-82.Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. | ||||
Ref 534044 | J Med Chem. 1993 Apr 2;36(7):842-7.Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. | ||||
Ref 529178 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. Epub 2007 Nov 17.Design and synthesis of a fluorescent muscarinic antagonist. | ||||
Ref 552190 | Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999 May;127(2):413-20. | ||||
Ref 552942 | Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin Ther Pat. 2009 Jan;19(1):1-12. doi: 10.1517/13543770802630331. | ||||
Ref 553131 | [3H]QNB binding and contraction of rabbit colonic smooth muscle cells. Am J Physiol. 1987 Nov;253(5 Pt 1):G656-61. | ||||
Ref 553144 | Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988 Feb;62(2):90-4. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.